Syndax (SNDX) Pharmaceuticals announced that the U.S. FDA has approved Revuforj as the first and only menin inhibitor for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application received approval through the FDA’s Real Time Oncology Review program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- FDA approves Syndax’s Revuforj for acute leukemia
- Biotech Alert: Searches spiking for these stocks today
- Charter to acquire Liberty Broadband, Spotify reports Q3 beat: Morning Buzz
- Syndax price target lowered to $18 from $23 at Scotiabank
- Leerink views Syndax data as potentially positive for Kura Oncology’s ziftomenib